Injective (INJ) surged 27% to $9.20 on a 1-year high, driven by CEO regulatory meeting; analysts target $14–$80 but RSI suggests overbought conditions.

Macro & Markets · 2026-10-16

Injective (INJ) surged 27% to $9.20, its highest price since October 2025, following a Washington meeting between its CEO and officials from the White House, SEC, and CFTC. Analysts have projected price targets ranging from $14 to $80 based on technical patterns, though the token's RSI near 80 indicates overbought conditions that could trigger near-term volatility around the $9 level.

Previously on Telem

Injective becomes first layer 1 blockchain registered with SEC as transfer agent 2026-10-12
Gulf Labs joins Injective as institutional validator, targets Thai tokenization 2026-10-08
Injective CEO expects US INJ ETF approvals before 2027 2026-10-05
Firelight Protocol launches DeFi vault protection backed by staked FXRP 2026-10-09
Injective releases first full whitepaper rewrite since 2018 2026-10-07